You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neoplasms, Plasma Cell

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Multiple Myeloma Cells From miRNAs Released From B Cells, and

Recruiting
  • Multiple Myeloma
    • Aviano, Pordenone, Italy
      Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
    Nov 23, 2023

    Chemo-induced Peripheral Neuropathy, Plasma Cell Myeloma Trial in Winston-Salem (VascuTherm5 vascular compression device)

    Recruiting
    • Chemotherapy-induced Peripheral Neuropathy
    • Plasma Cell Myeloma
    • VascuTherm5 vascular compression device
    • Winston-Salem, North Carolina
      Wake Forest Baptist Comprehensive Cancer Center
    Dec 16, 2022

    Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial in Wuhan (CAR-T (CAR-GPRC5D))

    Recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Plasma Cell Leukemia
    • CAR-T (CAR-GPRC5D)
    • Wuhan, Hu Bei, China
      Tongji Hospital, Tongji Medical College, Huazhong University of
    May 17, 2022

    Multiple Myeloma Trial in Saint Louis (Care transition, No care transition)

    Not yet recruiting
    • Multiple Myeloma
    • Care transition
    • No care transition
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jul 30, 2023

    Multiple Myeloma, New Diagnosis Tumor Trial in Hangzhou (BCMA CAR-T cells)

    Recruiting
    • Multiple Myeloma
    • New Diagnosis Tumor
    • BCMA CAR-T cells
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital, College of Medicine, Zhejiang Uni
    Jan 31, 2023

    Multiple Myeloma Trial in Rennes (Blood and bone marrow sampling)

    Completed
    • Multiple Myeloma
    • Blood and bone marrow sampling
    • Rennes, France
      CHU Rennes
    Feb 2, 2023

    Plasma Cell Myeloma Trial (Isatuximab (SAR650984), Cemiplimab (SAR439684), Dexamethasone)

    Not yet recruiting
    • Plasma Cell Myeloma
    • Isatuximab (SAR650984)
    • +4 more
    • (no location specified)
    Feb 1, 2023

    Plasma Cell Myeloma Trial in Buffalo (Belantamab Mafodotin, Lenalidomide)

    Recruiting
    • Plasma Cell Myeloma
    • Buffalo, New York
      Roswell Park Cancer Institute
    Dec 5, 2022

    Multiple Myeloma Trial in Wollongong (IBI3003)

    Not yet recruiting
    • Multiple Myeloma
    • Wollongong, New South Wales, Australia
      Wollongong Private Hospital
    Oct 18, 2023

    Multiple Myeloma Trial in Houston (Isatuximab, lenalidomide)

    Not yet recruiting
    • Multiple Myeloma
    • Houston, Texas
      M D Anderson Cancer Center
    Mar 8, 2023

    Multiple Myeloma Trial in Shanghai (GC012F injection)

    Not yet recruiting
    • Multiple Myeloma
    • GC012F injection
    • Shanghai, Shanghai, China
      Shanghai Changzheng Hospital
    May 1, 2023

    Host Microbiota and Il-17 in Favoring Multiple Myeloma

    Recruiting
    • Multiple Myeloma
      • Milan, Milano, Italy
        IRCCS Ospedale San Raffaele
      Jan 26, 2023

      ctDNA Methylation Sequencing for Myeloma

      Recruiting
      • Multiple Myeloma
      • plasma circulation DNA methylation sequencing
      • Tianjin, China
        Institute of Hematology and Blood Diseases Hospital Chinese Acad
      Oct 11, 2022

      Belantamab Mafodotin Care Patterns in Relapsed and/or Refractory

      Not yet recruiting
      • Multiple Myeloma
      • Durham, North Carolina
        Duke University Medical Center
      Aug 8, 2023

      Carfilzomib in Patients With Multiple Myeloma

      Recruiting
      • Multiple Myeloma
      • Odense, Denmark
        Odense University Hospital
      Dec 20, 2022

      Multiple Myeloma Trial in Montréal (Elranatamab)

      Not yet recruiting
      • Multiple Myeloma
      • MontrĂ©al, Quebec, Canada
        McGill University Health Centre
      Sep 21, 2023

      Smoldering Multiple Myeloma (SMM) Trial (Linvoseltamab)

      Not yet recruiting
      • Smoldering Multiple Myeloma (SMM)
      • (no location specified)
      Jul 13, 2023

      Relapsed and Refractory Multiple Myeloma Trial in Pittsburgh (Mezigdomide, Ixazomib, Dexamethasone)

      Not yet recruiting
      • Relapsed and Refractory Multiple Myeloma
      • Pittsburgh, Pennsylvania
        UPMC Hillman Cancer Center
      Sep 15, 2023

      Taste Function In Multiple Myeloma Patients Undergoing

      Active, not recruiting
      • Multiple Myeloma
      • Oral microbiota assessment
      • +3 more
      • New York, New York
        Memorial Sloan Kettering Cancer Center
      Jan 23, 2023

      Multiple Myeloma Trial in Roma, Rome (ChIP-seq, NGS, ATAC-seq)

      Recruiting
      • Multiple Myeloma
      • ChIP-seq, NGS, ATAC-seq
      • Roma, Italy
      • +1 more
      May 24, 2023

      Myeloma Trial in Houston (Fludarabine phosphate, Cyclophosphamide, NY-ESO-1 TCR/IL-15 NK)

      Not yet recruiting
      • Myeloma
      • Fludarabine phosphate
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Sep 27, 2023

      Multiple Myeloma Trial in Philadelphia (CART-19 cells)

      Terminated
      Has Results
      • Multiple Myeloma
      • CART-19 cells
      • Philadelphia, Pennsylvania
        Abramson Cancer Center of the University of Pennsylvania
      Jan 4, 2023

      Multiple Myeloma in Relapse, Multiple Myeloma, Refractory Trial (Venetoclax)

      Not yet recruiting
      • Multiple Myeloma in Relapse
      • Multiple Myeloma, Refractory
      • (no location specified)
      Oct 30, 2023

      Guiding the Treatment in Older Newly Diagnosed Multiple Myeloma

      Not yet recruiting
      • Multiple Myeloma
      • Frailty
        • (no location specified)
        Oct 30, 2023

        Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Relapsed and/or Refractory Multiple Myeloma (RRMM) Trial run by the

        Not yet recruiting
        • Multiple Myeloma
        • +2 more
        • 18F-fluciclovine injection
        • 18F-FDG PET/CT
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Oct 31, 2023